Overexpression of HER2 can also be seen in other tumors such as the ovary, endometrium, bladder, lung, colon, and head and neck. HER2 ADC targeted therapy has greatly improved the prognosis of HER2-positive breast and gastric/esophageal cancer patients; however, the efficacy of other HER2 overexpressing cancers has been disappointing.
Tom Held, the vice president and head of cancer research, said: "I am pleased to have the opportunity to work with Keytruda to assess the safety, tolerability and activity of DS-8201, and whether this combination can express advanced breast cancer for HER2 and patients with non-small cell lung cancer offer a potential new approach to ADC analysis. This strategic collaboration supports our goal of pursuing, researching and maximizing the use of DS-8201 in combination with other compounds for different pathways to address needs of cancer patients."
https://www.creative-biolabs.com/adc/target-erbb2-37.htm
